The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)-naïve HIV-infected patients

European Journal of Medical Research

Volumn 16, Issue 3, 2011, Pages 93-100

  Knechten, H ^a   Stephan, C ^b   Mosthaf, F A ^c   Jaeger, H ^d   Carganico, A ^e   Lutz, T ^f   Schewe, K ^g   Mayr, C ^h   Wolf, E ⁱ   Wellmann, E ^j   Tappe, A ^j  

^a Praxen Zentrum Blondelstrasse   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Practice Drs FA Mosthaf/M Procaccianti/K Zutavern Bechtold   (Germany)

^d HIV Research and Clinical Care Centre Munich   (Germany)

^e Praxis Dupke/Carganico/Baumgarten   (Germany)

^f Infektiologikum Frankfurt   (Germany)

^g Infektionsmedizinisches Centrum Hamburg   (Germany)

^h MVZ Aerzteforum Seestrasse Dres C Mayr / PD W Schmidt   (Germany)

ⁱ MUC Research GmbH and MVZ Karlsplatz   (Germany)

^j ROCHE INNOVATION CENTER MUNICH   (Germany)

more..

Author keywords

CD4 cells; HIV; HIV RNA; Lipids; Long term; Saquinavir; Treatment

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BILIRUBIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; TRIACYLGLYCEROL; VIRUS RNA; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DELUSIONAL DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGY; HEPATITIS B; HEPATITIS C; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MENTAL DISEASE; MIXED INFECTION; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; OBSERVATIONAL STUDY; RASH; SIDE EFFECT; SYPHILIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; COHORT ANALYSIS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACE RASH; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; NONHUMAN; PROSPECTIVE STUDY;

EID: 79954476885     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-3-93     Document Type: Article

References (14)

1. European AIDS Clinical Society Guidelines 2008. http://www. europeanaidsclinicalsociety.org/guidelinespdf/l-Treatment-of-HIV-Infected- Adults.pdf. Accessed November 16 2009.
2. German and Austrian guidelines for the diagnosis and therapy of HIV-infection. 2008. http://www.daignet.de/site-content/hiv-therapie/leitlinien- 1. Accessed November 16 2009.
3. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008 Aug 6; 300(5): 555-70.
4. Bittner B, Riek M, Holmes B, Grange S: Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther 2005; 10(7): 803-10. (Pubitemid 41652974)
5. Invirase® Summary of product characteristics. http://emc.medicines. org.uk/document.aspx?documentId=16123 Accessed March 3 2009.
6. Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD; Max-Cmin2 Trial Group: A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005; 10(6): 735-43. (Pubitemid 41376853)
7. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B; Staccato Thailand Study Group: Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008; 13(3): 375-80. (Pubitemid 352016730)
8. Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F: Gemini: A Non-inferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):367-74.
9. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD; MaxCmin1 Trial Group: Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003 Sep 1;188(5):635-42. (Pubitemid 37115175)
10. Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, Stoehr A, Koeppe S, Mayr C, Schewe K, Wolf E, Wellmann E, Tappe A. Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients. Infection 2010; 38(2): 108-116.
11. Salzberger B, Marcus U, Vielhaber B, Arasteh K, Gölz J, Brockmeyer NH, Rockstroh J: German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res. 2004 Nov 29; 9(11): 491-504.
12. Calza L, Manfredi R, Chiodo F: Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004Jan; 53(1): 10-4.
13. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, Pozniak A, Cooper DA, Phanuphak P, Lange JM, Ruxrungtham K, Burger DM: Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005 Nov; 56(5): 908-13. (Pubitemid 41631916)
14. Dickinson L, Boffito M, Back DJ, Khoo SH, Pozniak AL, Mugyenyi P, Merry C, Autar RS, Burger DM, Aarons LJ. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother. 2008 Dec; 62(6): 1344-55.